Search - tctmd.com

Displaying 101 - 120 of 142

Sort: Relevancy | Date

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

News Conference News ACC 2022

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

April 03, 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

April 03, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

March 22, 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

February 07, 2022

Modified Surgical MV Repair Stands Up to Replacement

News Conference News STS 2022

Modified Surgical MV Repair Stands Up to Replacement

Michael O'Riordan

February 03, 2022

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

December 07, 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

November 17, 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

November 14, 2021

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

News Daily News

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

September 20, 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

September 13, 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

News Conference News ESC 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

Yael L. Maxwell

September 03, 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

August 27, 2021

Heart Failure Patients With AF Benefit From Early Rhythm Control

News Conference News HRS 2021

Heart Failure Patients With AF Benefit From Early Rhythm Control

July 30, 2021

Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists

News Daily News

Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists

July 09, 2021

Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR

News Conference News ESC Heart Failure 2021

Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR

July 06, 2021

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

News Daily News

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

June 03, 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

News Conference News ACC 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

May 18, 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

News Conference News ACC 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

May 15, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.